Pfizer and Genmab's Ongoing Clinical Study: Assessing Tivdak's Ocular Safety in Cervical Cancer Treatment

Pfizer and Genmab are conducting a Phase 4 clinical study to assess ocular safety in cervical cancer patients treated with Tivdak. The study aims to evaluate potential ocular side effects and improve patient care. Tivdak is a treatment for recurrent or metastatic cervical cancer, and the study will assess ocular side effects in participants who receive the drug. The study began on May 7, 2025, and is currently recruiting participants.